Injective Rallies on ETF Staking Plan and Phantom Launch

Injective extended its advance after two developments sharpened investor attention: 21Shares filed an updated S-1 for its proposed Injective exchange-traded fund, and the network launched on Phantom. The token rose more than 17% as traders weighed the prospect of regulated exposure and broader wallet access.

The 21Shares filing is notable because it outlines a potential staking allocation of 40% to 60% of the fund’s INJ holdings. If approved and implemented, that structure could allow the product to capture staking yield while maintaining ETF exposure, a combination that may appeal to investors seeking both price participation and protocol-linked income.

Separately, Injective’s integration with Phantom expands access to the token across one of the crypto sector’s most widely used wallets. Distribution improvements do not change fundamentals on their own, but they can support liquidity, improve user reach and reinforce network visibility at a time when market participants are rotating toward assets with active ecosystem development.

The move comes as the broader crypto market trades with a constructive tone. The Fear and Greed Index at 71 suggests risk appetite remains elevated, which can amplify upside in assets tied to fresh catalysts. Still, the rally appears driven more by event-specific headlines than by a broad repricing of Injective’s long-term valuation.

Investors will now watch whether 21Shares’ ETF proposal advances through the next regulatory stages and whether the Phantom listing translates into sustained on-chain activity. For now, Injective has a clear near-term narrative: institutional access, staking economics and wider retail distribution.